Immunocore Could Gain Green Light For First T-Cell Receptor Drug In Early 2022

Tebentafusp Granted Rare EU Accelerated Assessment

The UK biotech is the first company to file a T-cell receptor therapy with regulators, a class with potential to hit targets unreachable for antibodies and CAR-Ts.

EMA
Rapid assessment US and EU reviews could see tebentafusp become the TCR receptor therapy approved in early 2022

Immunocore has filed its potential first-in-class T-cell receptor drug tebentafusp (IMCgp100) with regulators on both sides of the Atlantic, and the product could gain its first approval by February 2022.

The UK biotech, which has been around since 2008, is a pioneer in the field of T-cell receptor (TCR) therapies,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip

Stock Watch: Q2 Sales Growth Sparks Diverging Reactions To J&J And Novartis

 
• By 

With drug sector indexes underperforming the broad market in the first half of 2025, investors may have been anticipating tariff-related and other headwinds. But impending loss of exclusivity on key products may be provoking more anxiety at this point.

Sanofi Doubles Down On Respiratory Vaccines With Vicebio Buy

 
• By 

The French major is paying $1.15bn For the UK biotech and its bivalent candidate, VXB-241.

Chinese Biotechs Sweep ADC Plus PD-(L)1/VEGF Bispecific Combos Into Phase II

 

Chinese firms Junshi, Minghui and RemeGen rank among the world’s few players progressing antibody-drug conjugates combined with PD-(L)1/VEGF bispecific antibodies in Phase II trials for various cancers.